Faculty of Pharmacy, Department of Bioorganic & Pharmaceutical Chemistry, Al-Quds University, Jerusalem P.O. Box 20002, Palestine.
Institute of Pathology, Rabin Medical Centre, PetachTikva 49100, Israel.
Molecules. 2020 Feb 17;25(4):884. doi: 10.3390/molecules25040884.
The design and development of prodrugs is the most common and effective strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected number of prodrugs have been reached the drugs market throughout history and the recent years have witnessed a significant increase in the use of prodrugs as a replacement of their parent drugs for an efficient treatment of various ailment.
A Scan conducted to find recent approved prodrugs and prodrugs in development.
Selected prodrugs were reported and categorized in accordance to their target systems.
the prodrug approach has shown many successes and still remains a viable and effective approach to deliver new active agents. This conclusion is supported by the recent approved prodrugs and the scan of clinical trials conducted between 2013-2018.
前药的设计和开发是克服活性药物药代动力学和药效学缺陷最常见和最有效的策略。历史上已经有相当数量的前药进入了药物市场，近年来，前药作为其母体药物的替代品被广泛用于有效治疗各种疾病，其使用显著增加。
扫描以寻找最近批准的前药和正在开发的前药。
根据目标系统对选定的前药进行了报道和分类。
前药方法已经取得了许多成功，仍然是一种可行且有效的方法，可以输送新的有效药物。这一结论得到了最近批准的前药和 2013-2018 年期间进行的临床试验扫描的支持。
